Pharmacokinetics of a long-circulating PEGylated radix ophiopogonis polysaccharide

Yaoxue Xuebao

Volumn 46, Issue 10, 2011, Pages 1257-1261

  Wang, Zhuo Jun ^a,b   Lin, Xiao ^a,b   Shen, Lan ^b   Feng, Yi ^a   Xu, De Sheng ^c   Ruan, Ke Feng ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b Shanghai Innovation Center of Traditional Chinese Medicine Health Service   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Pharmacokinetics; Polyethylene glycol; Polysaccharide; Radix ophiopogonis

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; OPHIOPOGON ROOT; POLYSACCHARIDE; RADIX OPHIOPOGONIS POLYSACCHARIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CROSS COUPLING REACTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; GEL PERMEATION CHROMATOGRAPHY; NONHUMAN;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUGS, CHINESE HERBAL; HALF-LIFE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; OPHIOPOGON; PLANT ROOTS; PLANTS, MEDICINAL; POLYETHYLENE GLYCOLS; POLYSACCHARIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 83455200407     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Xu DS, Feng Y, Lin X, et al. Isolation, purification and structural analysis of a polysaccharide MDG-1 from Ophiopogon japonicus [J]. Acta Pharm Sin, 2005, 40: 636-639. (Pubitemid 41260343)
2. Xu DS, Feng Y, Zhou YH, et al. Active components of polysaccharide of Ophiopogon japonicus on acute myocardial ischemia [J]. Chin Tradit Pat Med, 2006, 26: 832-837.
3. Wang S, Zhang Z, Lin X, et al. A polysaccharides, MDG-1, induces S1P and bFGF expression and augments survival and angiogenesis in the ischemic heart [J]. Glycobiology, 2010, 20: 473-484.
4. Lin X, Xu DS, Feng Y, et al. Determination of Ophiopogon japonicus polysaccharide in plasma by HPLC with modified postcolumn fluorescence derivatization [J]. Anal Biochem, 2005, 342: 179-185. (Pubitemid 40884564)
5. Kang JS, DeLuca PP, Lee KC. Emerging PEGylated drugs [J]. Expert Opin Emerg Drugs, 2009, 14: 363-380.
6. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals [J]. Nat Rev Drug Discov, 2003, 2: 214-221. (Pubitemid 37361666)
7. Veronese FM (Ed). PEGylated Protein Drugs: Basic Science and Clinical Applications [M]. Berlin: Birkhäuser Basel, 2009: 147-148.
8. Ryan SM, Mantovani G, Wang X, et al. Advances in PEGylation of important biotech molecules: delivery aspects [J]. Expert Opin Drug Deliv, 2008, 5: 371-383. (Pubitemid 351721718)
9. Lin X, Wang S, Jiang Y, et al. Poly(ethylene glycol)-Radix Ophiopogonis polysaccharide conjugates: preparation, characterization, pharmacokinetics and in vitro bioactivity [J]. Eur J Pharm Biopharm, 2010, 76: 230-237.
10. Lukyanov AN, Hartner WC, Torchilin VP. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits [J]. J Control Release, 2004, 94: 187-193. (Pubitemid 37542388)
11. Torchilin VP, Narula J, Halpern E, et al. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infracted myocardium [J]. Biochim Biophys Acta, 1996, 1279: 75-83. (Pubitemid 26067420)
12. Lin X, Wang Z, Sun G, et al. A sensitive and specific HPGPC-FD method for the study of pharmacokinetics and tissue distribution of Radix Ophiopogonis polysaccharide in rats [J]. Biomed Chromatogr, 2010, 24: 820-825.